Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genes, BRCA1 | 76 | 2024 | 756 | 6.530 |
Why?
|
BRCA1 Protein | 89 | 2024 | 1156 | 6.340 |
Why?
|
Breast Neoplasms | 174 | 2025 | 21187 | 5.510 |
Why?
|
BRCA2 Protein | 75 | 2024 | 803 | 5.490 |
Why?
|
Germ-Line Mutation | 43 | 2024 | 1887 | 5.170 |
Why?
|
Genes, BRCA2 | 66 | 2024 | 593 | 5.040 |
Why?
|
Ovarian Neoplasms | 71 | 2024 | 4919 | 3.530 |
Why?
|
Genetic Testing | 23 | 2024 | 3590 | 2.710 |
Why?
|
Genetic Predisposition to Disease | 93 | 2024 | 18065 | 2.090 |
Why?
|
Mutation | 118 | 2024 | 30266 | 2.080 |
Why?
|
Heterozygote | 62 | 2024 | 2798 | 2.000 |
Why?
|
Receptors, Estrogen | 20 | 2022 | 2252 | 1.730 |
Why?
|
Ovariectomy | 24 | 2024 | 615 | 1.720 |
Why?
|
Receptor, erbB-2 | 24 | 2024 | 2606 | 1.620 |
Why?
|
Germ Cells | 6 | 2022 | 644 | 1.400 |
Why?
|
Phthalazines | 9 | 2023 | 397 | 1.350 |
Why?
|
Genetic Counseling | 6 | 2019 | 634 | 1.300 |
Why?
|
Cisplatin | 7 | 2020 | 1661 | 1.080 |
Why?
|
Neoadjuvant Therapy | 14 | 2023 | 2909 | 0.940 |
Why?
|
Mastectomy | 20 | 2024 | 1850 | 0.890 |
Why?
|
Aromatase Inhibitors | 4 | 2025 | 519 | 0.840 |
Why?
|
Li-Fraumeni Syndrome | 2 | 2021 | 117 | 0.800 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11886 | 0.780 |
Why?
|
Doxorubicin | 4 | 2024 | 2234 | 0.770 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2014 | 1093 | 0.770 |
Why?
|
Tamoxifen | 13 | 2024 | 967 | 0.760 |
Why?
|
Female | 224 | 2025 | 397464 | 0.760 |
Why?
|
Antineoplastic Agents, Hormonal | 8 | 2014 | 1535 | 0.720 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2024 | 3554 | 0.720 |
Why?
|
Pancreatic Neoplasms | 9 | 2024 | 5443 | 0.710 |
Why?
|
Piperazines | 6 | 2020 | 2553 | 0.630 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 1105 | 0.610 |
Why?
|
Cyclophosphamide | 3 | 2020 | 2227 | 0.600 |
Why?
|
Humans | 242 | 2025 | 768887 | 0.580 |
Why?
|
Middle Aged | 135 | 2025 | 223740 | 0.570 |
Why?
|
Fibrocystic Breast Disease | 1 | 2017 | 103 | 0.570 |
Why?
|
Mammography | 7 | 2020 | 2434 | 0.560 |
Why?
|
Adult | 136 | 2024 | 223818 | 0.550 |
Why?
|
Neoplasms, Second Primary | 8 | 2017 | 1060 | 0.530 |
Why?
|
Tumor Suppressor Proteins | 5 | 2017 | 2813 | 0.520 |
Why?
|
Breast | 5 | 2022 | 1976 | 0.510 |
Why?
|
Genetic Association Studies | 6 | 2019 | 2747 | 0.490 |
Why?
|
Carboplatin | 4 | 2021 | 799 | 0.470 |
Why?
|
Aged | 96 | 2025 | 171790 | 0.450 |
Why?
|
Neoplasms | 8 | 2024 | 22390 | 0.420 |
Why?
|
Polymorphism, Single Nucleotide | 23 | 2022 | 16051 | 0.420 |
Why?
|
Paclitaxel | 8 | 2024 | 1735 | 0.420 |
Why?
|
Genome-Wide Association Study | 15 | 2021 | 12798 | 0.410 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2016 | 3671 | 0.410 |
Why?
|
Practice Guidelines as Topic | 7 | 2024 | 7460 | 0.410 |
Why?
|
Patients | 1 | 2019 | 908 | 0.400 |
Why?
|
Neoplasm Staging | 20 | 2024 | 11262 | 0.400 |
Why?
|
Receptors, Progesterone | 8 | 2021 | 1159 | 0.390 |
Why?
|
Ubiquitin-Protein Ligases | 4 | 2017 | 1903 | 0.390 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2023 | 1756 | 0.390 |
Why?
|
Jews | 7 | 2022 | 359 | 0.380 |
Why?
|
Poly(ADP-ribose) Polymerases | 3 | 2020 | 428 | 0.370 |
Why?
|
Risk Factors | 64 | 2024 | 74971 | 0.350 |
Why?
|
Family | 3 | 2019 | 3208 | 0.320 |
Why?
|
Genomics | 5 | 2024 | 5928 | 0.320 |
Why?
|
Axilla | 1 | 2011 | 625 | 0.310 |
Why?
|
Age Factors | 19 | 2020 | 18454 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 9442 | 0.280 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2017 | 489 | 0.280 |
Why?
|
Medical Oncology | 4 | 2020 | 2350 | 0.270 |
Why?
|
Pregnancy Complications, Neoplastic | 3 | 2016 | 259 | 0.270 |
Why?
|
Prospective Studies | 32 | 2024 | 54950 | 0.260 |
Why?
|
Carcinoma | 5 | 2020 | 2340 | 0.260 |
Why?
|
Alleles | 10 | 2022 | 6901 | 0.260 |
Why?
|
Case-Control Studies | 31 | 2023 | 22294 | 0.250 |
Why?
|
Genotype | 17 | 2021 | 13048 | 0.250 |
Why?
|
Fallopian Tube Neoplasms | 4 | 2020 | 329 | 0.250 |
Why?
|
Standard of Care | 2 | 2022 | 570 | 0.250 |
Why?
|
Aged, 80 and over | 32 | 2024 | 59738 | 0.250 |
Why?
|
Endometrial Neoplasms | 3 | 2024 | 1386 | 0.250 |
Why?
|
Gene Expression Profiling | 4 | 2019 | 9549 | 0.250 |
Why?
|
Communication | 1 | 2019 | 3908 | 0.240 |
Why?
|
Risk Assessment | 22 | 2022 | 24330 | 0.240 |
Why?
|
Early Detection of Cancer | 6 | 2023 | 3238 | 0.230 |
Why?
|
Prognosis | 25 | 2024 | 30044 | 0.230 |
Why?
|
Risk Reduction Behavior | 5 | 2019 | 1119 | 0.230 |
Why?
|
Allelic Imbalance | 2 | 2016 | 77 | 0.220 |
Why?
|
Odds Ratio | 20 | 2022 | 9682 | 0.220 |
Why?
|
Incidence | 18 | 2024 | 21545 | 0.220 |
Why?
|
Neoplasm Metastasis | 5 | 2020 | 4926 | 0.220 |
Why?
|
Quantitative Trait Loci | 7 | 2021 | 2133 | 0.220 |
Why?
|
Mendelian Randomization Analysis | 2 | 2019 | 1040 | 0.210 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4784 | 0.210 |
Why?
|
Peritoneal Neoplasms | 3 | 2024 | 714 | 0.210 |
Why?
|
Body Height | 2 | 2019 | 1568 | 0.210 |
Why?
|
Chromosomes, Human, Pair 19 | 2 | 2016 | 350 | 0.210 |
Why?
|
Young Adult | 30 | 2021 | 60110 | 0.200 |
Why?
|
Swine, Miniature | 1 | 2024 | 965 | 0.190 |
Why?
|
Population Surveillance | 5 | 2019 | 2597 | 0.190 |
Why?
|
Hormone Replacement Therapy | 2 | 2018 | 756 | 0.190 |
Why?
|
Genetic Variation | 8 | 2021 | 6610 | 0.180 |
Why?
|
Chromosome Mapping | 3 | 2020 | 4624 | 0.180 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2021 | 2960 | 0.180 |
Why?
|
Postmenopause | 2 | 2025 | 2519 | 0.180 |
Why?
|
Gonadal Steroid Hormones | 1 | 2025 | 708 | 0.180 |
Why?
|
Adenocarcinoma | 1 | 2018 | 6401 | 0.180 |
Why?
|
Maytansine | 1 | 2021 | 88 | 0.180 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 196 | 0.180 |
Why?
|
Genes, p53 | 3 | 2019 | 716 | 0.180 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 878 | 0.170 |
Why?
|
Oxazoles | 1 | 2021 | 199 | 0.170 |
Why?
|
Contraceptives, Oral | 3 | 2022 | 560 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.170 |
Why?
|
Breast Feeding | 3 | 2020 | 1364 | 0.170 |
Why?
|
Physicians | 3 | 2023 | 4607 | 0.170 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2018 | 2525 | 0.160 |
Why?
|
Canada | 8 | 2020 | 2129 | 0.160 |
Why?
|
Predictive Value of Tests | 7 | 2024 | 15471 | 0.160 |
Why?
|
Cohort Studies | 23 | 2024 | 41800 | 0.160 |
Why?
|
Taxoids | 4 | 2023 | 668 | 0.160 |
Why?
|
Myocardium | 2 | 2024 | 4790 | 0.160 |
Why?
|
Chromosomal Instability | 1 | 2019 | 176 | 0.150 |
Why?
|
Carcinoma, Lobular | 2 | 2014 | 480 | 0.150 |
Why?
|
Loss of Heterozygosity | 3 | 2016 | 663 | 0.150 |
Why?
|
DNA Mutational Analysis | 9 | 2015 | 4123 | 0.150 |
Why?
|
Cross-Over Studies | 1 | 2025 | 2108 | 0.150 |
Why?
|
Gene Frequency | 5 | 2019 | 3625 | 0.150 |
Why?
|
Endpoint Determination | 1 | 2021 | 594 | 0.150 |
Why?
|
Risk | 11 | 2022 | 9621 | 0.150 |
Why?
|
Menopause | 3 | 2019 | 1656 | 0.150 |
Why?
|
RecQ Helicases | 1 | 2018 | 53 | 0.150 |
Why?
|
Nuclear Proteins | 3 | 2011 | 5803 | 0.150 |
Why?
|
Brain Neoplasms | 4 | 2021 | 9213 | 0.150 |
Why?
|
Telomere | 2 | 2016 | 943 | 0.150 |
Why?
|
Platinum Compounds | 1 | 2018 | 95 | 0.150 |
Why?
|
Cysts | 1 | 2023 | 685 | 0.140 |
Why?
|
Memory | 1 | 2007 | 2210 | 0.140 |
Why?
|
Survival Rate | 9 | 2021 | 12873 | 0.140 |
Why?
|
Antineoplastic Agents | 6 | 2018 | 13699 | 0.140 |
Why?
|
Lymphatic Metastasis | 4 | 2019 | 2916 | 0.140 |
Why?
|
Quinolines | 2 | 2019 | 772 | 0.140 |
Why?
|
Linkage Disequilibrium | 6 | 2021 | 1998 | 0.140 |
Why?
|
Reproductive History | 1 | 2018 | 210 | 0.140 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 419 | 0.140 |
Why?
|
Saliva | 1 | 2021 | 855 | 0.140 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2024 | 1092 | 0.140 |
Why?
|
Penetrance | 2 | 2016 | 386 | 0.140 |
Why?
|
Inheritance Patterns | 1 | 2019 | 344 | 0.140 |
Why?
|
Quinazolines | 2 | 2021 | 1373 | 0.140 |
Why?
|
Carbolines | 1 | 2018 | 296 | 0.130 |
Why?
|
Urogenital Neoplasms | 1 | 2017 | 132 | 0.130 |
Why?
|
Alcohol Drinking | 2 | 2025 | 4045 | 0.130 |
Why?
|
Pedigree | 6 | 2017 | 4545 | 0.130 |
Why?
|
DNA Repair | 2 | 2018 | 2054 | 0.130 |
Why?
|
Mosaicism | 1 | 2019 | 481 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 976 | 0.130 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1064 | 0.130 |
Why?
|
Haplotypes | 5 | 2016 | 2725 | 0.130 |
Why?
|
Infertility | 2 | 2015 | 654 | 0.130 |
Why?
|
Breast Neoplasms, Male | 2 | 2016 | 212 | 0.130 |
Why?
|
Codon, Terminator | 1 | 2015 | 125 | 0.120 |
Why?
|
DNA Damage | 2 | 2018 | 2472 | 0.120 |
Why?
|
Retrospective Studies | 18 | 2023 | 81892 | 0.120 |
Why?
|
Genes, Mitochondrial | 1 | 2015 | 59 | 0.120 |
Why?
|
Androstadienes | 2 | 2016 | 348 | 0.120 |
Why?
|
Follow-Up Studies | 15 | 2023 | 39394 | 0.120 |
Why?
|
Truth Disclosure | 1 | 2019 | 433 | 0.120 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2016 | 432 | 0.120 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2016 | 370 | 0.120 |
Why?
|
Time Factors | 11 | 2024 | 40266 | 0.120 |
Why?
|
Patient Satisfaction | 1 | 2007 | 3489 | 0.120 |
Why?
|
Mammaplasty | 2 | 2016 | 1263 | 0.120 |
Why?
|
Physicians, Primary Care | 1 | 2021 | 625 | 0.120 |
Why?
|
Pathology | 1 | 2017 | 270 | 0.120 |
Why?
|
Proportional Hazards Models | 9 | 2024 | 12563 | 0.120 |
Why?
|
Ovary | 1 | 2019 | 965 | 0.120 |
Why?
|
Pancreatitis, Chronic | 1 | 2017 | 282 | 0.110 |
Why?
|
Cadherins | 2 | 2010 | 906 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2015 | 202 | 0.110 |
Why?
|
Boston | 3 | 2020 | 9375 | 0.110 |
Why?
|
Treatment Outcome | 15 | 2023 | 65485 | 0.110 |
Why?
|
Radiotherapy | 1 | 2021 | 1506 | 0.110 |
Why?
|
Disease-Free Survival | 5 | 2024 | 6856 | 0.110 |
Why?
|
Head and Neck Neoplasms | 2 | 2019 | 2931 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2020 | 572 | 0.110 |
Why?
|
Prostatic Neoplasms | 5 | 2019 | 11229 | 0.110 |
Why?
|
Oncogenes | 1 | 2019 | 1236 | 0.110 |
Why?
|
Contraceptives, Oral, Hormonal | 2 | 2007 | 190 | 0.110 |
Why?
|
Ventricular Function, Left | 2 | 2024 | 3941 | 0.110 |
Why?
|
Body Mass Index | 3 | 2021 | 13054 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 13020 | 0.100 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2012 | 558 | 0.100 |
Why?
|
Colorectal Neoplasms | 4 | 2019 | 6982 | 0.100 |
Why?
|
Internationality | 1 | 2018 | 1008 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 4053 | 0.100 |
Why?
|
Stroke Volume | 2 | 2024 | 5621 | 0.100 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2014 | 737 | 0.100 |
Why?
|
Immunohistochemistry | 5 | 2018 | 11119 | 0.100 |
Why?
|
North America | 6 | 2014 | 1290 | 0.100 |
Why?
|
Decision Making | 2 | 2007 | 3952 | 0.100 |
Why?
|
Estrogen Receptor alpha | 1 | 2016 | 581 | 0.100 |
Why?
|
Menopause, Premature | 1 | 2013 | 124 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2017 | 788 | 0.090 |
Why?
|
Primary Prevention | 2 | 2010 | 1187 | 0.090 |
Why?
|
Polychondritis, Relapsing | 1 | 2011 | 29 | 0.090 |
Why?
|
Mesothelioma | 1 | 2017 | 811 | 0.090 |
Why?
|
Survival Analysis | 6 | 2019 | 10115 | 0.090 |
Why?
|
Genes, myc | 1 | 2012 | 391 | 0.090 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2015 | 503 | 0.090 |
Why?
|
Weight Gain | 1 | 2021 | 2359 | 0.090 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 930 | 0.090 |
Why?
|
Tissue Array Analysis | 1 | 2012 | 551 | 0.090 |
Why?
|
Risk Management | 2 | 2024 | 558 | 0.090 |
Why?
|
Motivation | 1 | 2020 | 2030 | 0.090 |
Why?
|
Societies, Medical | 2 | 2020 | 3967 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2020 | 2008 | 0.090 |
Why?
|
Europe | 6 | 2014 | 3441 | 0.090 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 933 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2019 | 2059 | 0.090 |
Why?
|
Primary Health Care | 3 | 2022 | 4748 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1814 | 0.080 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2017 | 957 | 0.080 |
Why?
|
Genetic Loci | 2 | 2017 | 2630 | 0.080 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2011 | 271 | 0.080 |
Why?
|
Disease Management | 2 | 2018 | 2537 | 0.080 |
Why?
|
Neoplasm Proteins | 5 | 2022 | 3608 | 0.080 |
Why?
|
Mass Screening | 2 | 2020 | 5455 | 0.080 |
Why?
|
Phenotype | 10 | 2020 | 16735 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2896 | 0.080 |
Why?
|
Ketones | 2 | 2021 | 183 | 0.080 |
Why?
|
Research | 1 | 2018 | 1981 | 0.080 |
Why?
|
Furans | 2 | 2021 | 202 | 0.080 |
Why?
|
Sarcoma, Kaposi | 1 | 2012 | 375 | 0.080 |
Why?
|
Keratins | 1 | 2010 | 502 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 8664 | 0.080 |
Why?
|
Platinum | 2 | 2023 | 222 | 0.080 |
Why?
|
Wine | 2 | 2025 | 172 | 0.080 |
Why?
|
DNA, Neoplasm | 1 | 2014 | 1748 | 0.080 |
Why?
|
Medical History Taking | 2 | 2019 | 779 | 0.080 |
Why?
|
Somatomedins | 1 | 2009 | 179 | 0.080 |
Why?
|
Age of Onset | 7 | 2015 | 3346 | 0.080 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2011 | 506 | 0.080 |
Why?
|
Research Design | 3 | 2021 | 6213 | 0.080 |
Why?
|
Necrosis | 1 | 2012 | 1621 | 0.070 |
Why?
|
Adolescent | 20 | 2023 | 89247 | 0.070 |
Why?
|
Lymph Node Excision | 1 | 2014 | 1273 | 0.070 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 208 | 0.070 |
Why?
|
Microarray Analysis | 1 | 2010 | 755 | 0.070 |
Why?
|
Leukemia | 1 | 2016 | 1520 | 0.070 |
Why?
|
Immunophenotyping | 1 | 2012 | 1866 | 0.070 |
Why?
|
Antidepressive Agents | 1 | 2020 | 2914 | 0.070 |
Why?
|
Nitriles | 1 | 2013 | 990 | 0.070 |
Why?
|
Triazoles | 1 | 2013 | 904 | 0.070 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2012 | 480 | 0.070 |
Why?
|
Fertilization in Vitro | 2 | 2015 | 1302 | 0.070 |
Why?
|
Cluster Analysis | 2 | 2012 | 2730 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 4 | 2024 | 6546 | 0.070 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8559 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1769 | 0.070 |
Why?
|
Prevalence | 4 | 2023 | 15875 | 0.070 |
Why?
|
Deafness | 1 | 2011 | 462 | 0.070 |
Why?
|
Carcinoma, Large Cell | 1 | 2007 | 114 | 0.070 |
Why?
|
Disease Models, Animal | 2 | 2024 | 18366 | 0.070 |
Why?
|
Evidence-Based Medicine | 2 | 2016 | 3709 | 0.070 |
Why?
|
Cell Cycle Proteins | 2 | 2016 | 3450 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 6 | 2024 | 36861 | 0.070 |
Why?
|
Abortion, Therapeutic | 1 | 2006 | 35 | 0.070 |
Why?
|
Chi-Square Distribution | 4 | 2015 | 3438 | 0.070 |
Why?
|
PTEN Phosphohydrolase | 1 | 2012 | 1120 | 0.070 |
Why?
|
Heart Diseases | 1 | 2019 | 2819 | 0.070 |
Why?
|
Serine Endopeptidases | 1 | 2011 | 1027 | 0.060 |
Why?
|
International Agencies | 2 | 2019 | 244 | 0.060 |
Why?
|
Codon, Nonsense | 1 | 2007 | 287 | 0.060 |
Why?
|
Logistic Models | 7 | 2015 | 13317 | 0.060 |
Why?
|
Founder Effect | 2 | 2011 | 185 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1793 | 0.060 |
Why?
|
Arthritis | 1 | 2011 | 684 | 0.060 |
Why?
|
Forecasting | 2 | 2014 | 2946 | 0.060 |
Why?
|
Menarche | 2 | 2005 | 538 | 0.060 |
Why?
|
Multicenter Studies as Topic | 2 | 2021 | 1737 | 0.060 |
Why?
|
Fibrosis | 1 | 2012 | 2081 | 0.060 |
Why?
|
Carrier Proteins | 2 | 2016 | 4940 | 0.060 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2007 | 249 | 0.060 |
Why?
|
beta Catenin | 1 | 2010 | 1047 | 0.060 |
Why?
|
Longitudinal Studies | 4 | 2024 | 14795 | 0.060 |
Why?
|
Male | 19 | 2023 | 365249 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 13510 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13593 | 0.050 |
Why?
|
Meta-Analysis as Topic | 2 | 2019 | 1364 | 0.050 |
Why?
|
Smoking | 3 | 2019 | 9094 | 0.050 |
Why?
|
Rural Health | 1 | 2004 | 300 | 0.050 |
Why?
|
Bayes Theorem | 2 | 2022 | 2357 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 2007 | 1157 | 0.050 |
Why?
|
Chemoprevention | 1 | 2004 | 326 | 0.050 |
Why?
|
Mullerian Ducts | 1 | 2003 | 203 | 0.050 |
Why?
|
Parity | 3 | 2014 | 930 | 0.050 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2025 | 554 | 0.050 |
Why?
|
Fertility Agents, Female | 2 | 2015 | 101 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4064 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 628 | 0.050 |
Why?
|
DNA Methylation | 3 | 2010 | 4432 | 0.050 |
Why?
|
Cell Division | 1 | 2009 | 4478 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6085 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3463 | 0.050 |
Why?
|
Transcription Factors | 5 | 2022 | 12174 | 0.050 |
Why?
|
Coffee | 1 | 2006 | 594 | 0.050 |
Why?
|
Administration, Oral | 2 | 2019 | 4042 | 0.050 |
Why?
|
Pancreatic Ducts | 1 | 2023 | 330 | 0.050 |
Why?
|
Sterilization, Tubal | 1 | 2001 | 78 | 0.050 |
Why?
|
Abortion, Spontaneous | 1 | 2006 | 534 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3724 | 0.050 |
Why?
|
Epithelial Cells | 2 | 2011 | 3701 | 0.050 |
Why?
|
Qualitative Research | 2 | 2022 | 3143 | 0.040 |
Why?
|
Postal Service | 1 | 2020 | 96 | 0.040 |
Why?
|
Melanoma | 2 | 2017 | 5709 | 0.040 |
Why?
|
Cell Line, Tumor | 5 | 2020 | 17174 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2024 | 682 | 0.040 |
Why?
|
Retinal Dehydrogenase | 2 | 2011 | 78 | 0.040 |
Why?
|
Databases, Genetic | 2 | 2018 | 1758 | 0.040 |
Why?
|
Genes, APC | 1 | 2000 | 146 | 0.040 |
Why?
|
Depression | 1 | 2020 | 8240 | 0.040 |
Why?
|
Philadelphia | 1 | 2020 | 271 | 0.040 |
Why?
|
Poland | 1 | 2020 | 197 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 631 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2018 | 10778 | 0.040 |
Why?
|
Pregnancy | 8 | 2016 | 30175 | 0.040 |
Why?
|
RNA, Messenger | 4 | 2022 | 12809 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 715 | 0.040 |
Why?
|
Promoter Regions, Genetic | 3 | 2016 | 5801 | 0.040 |
Why?
|
Pilot Projects | 2 | 2025 | 8742 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5434 | 0.040 |
Why?
|
Tablets | 1 | 2019 | 149 | 0.040 |
Why?
|
Etoposide | 1 | 2000 | 639 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2003 | 888 | 0.040 |
Why?
|
Estrogens | 2 | 2020 | 1537 | 0.040 |
Why?
|
Recurrence | 1 | 2011 | 8512 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5864 | 0.040 |
Why?
|
Women's Health | 1 | 2007 | 2081 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26384 | 0.040 |
Why?
|
Anxiety | 2 | 2021 | 4677 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3540 | 0.040 |
Why?
|
Sus scrofa | 1 | 2019 | 430 | 0.040 |
Why?
|
Learning | 1 | 2007 | 1761 | 0.040 |
Why?
|
Amenorrhea | 1 | 2021 | 484 | 0.040 |
Why?
|
Estradiol | 1 | 2025 | 1952 | 0.040 |
Why?
|
Annual Reports as Topic | 1 | 2017 | 36 | 0.040 |
Why?
|
United States | 7 | 2021 | 73180 | 0.040 |
Why?
|
Stress, Psychological | 1 | 2013 | 4542 | 0.040 |
Why?
|
Vesicular Transport Proteins | 1 | 2020 | 377 | 0.040 |
Why?
|
Placebos | 1 | 2021 | 1668 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 640 | 0.030 |
Why?
|
Counseling | 1 | 2004 | 1554 | 0.030 |
Why?
|
Hormones | 1 | 2020 | 871 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 892 | 0.030 |
Why?
|
Cyclophilins | 1 | 2016 | 47 | 0.030 |
Why?
|
Telomere-Binding Proteins | 1 | 2017 | 122 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1019 | 0.030 |
Why?
|
tRNA Methyltransferases | 1 | 2016 | 50 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 864 | 0.030 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2020 | 792 | 0.030 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2016 | 131 | 0.030 |
Why?
|
Geography | 1 | 2018 | 654 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 2001 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2016 | 411 | 0.030 |
Why?
|
Colonic Polyps | 1 | 2000 | 557 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4862 | 0.030 |
Why?
|
Isoenzymes | 2 | 2011 | 1687 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2299 | 0.030 |
Why?
|
Insemination, Artificial | 1 | 2015 | 99 | 0.030 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2016 | 313 | 0.030 |
Why?
|
Heredity | 1 | 2015 | 149 | 0.030 |
Why?
|
Advisory Committees | 1 | 2019 | 797 | 0.030 |
Why?
|
Craniotomy | 1 | 2019 | 747 | 0.030 |
Why?
|
Neutropenia | 1 | 2000 | 893 | 0.030 |
Why?
|
Malaria | 1 | 2004 | 1241 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2004 | 2339 | 0.030 |
Why?
|
Matched-Pair Analysis | 2 | 2007 | 286 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2019 | 568 | 0.030 |
Why?
|
Base Sequence | 3 | 2016 | 12430 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2019 | 1195 | 0.030 |
Why?
|
Ovulation | 1 | 2014 | 181 | 0.030 |
Why?
|
Myocardial Contraction | 1 | 2019 | 1526 | 0.030 |
Why?
|
Swine | 1 | 2024 | 5998 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 3629 | 0.030 |
Why?
|
Age Distribution | 2 | 2012 | 2875 | 0.030 |
Why?
|
Methylene Blue | 1 | 2014 | 156 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2024 | 3782 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2022 | 2055 | 0.030 |
Why?
|
Gene Expression | 2 | 2016 | 7602 | 0.030 |
Why?
|
Ultrasonography, Mammary | 1 | 2015 | 241 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2015 | 12093 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2884 | 0.030 |
Why?
|
Endosonography | 1 | 2017 | 626 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2024 | 2145 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2016 | 15889 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2017 | 696 | 0.030 |
Why?
|
Nucleotides | 1 | 2015 | 455 | 0.030 |
Why?
|
Breast Implants | 1 | 2016 | 414 | 0.030 |
Why?
|
Adult Children | 1 | 2013 | 104 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2009 | 11684 | 0.020 |
Why?
|
Fear | 1 | 2021 | 1494 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2000 | 1181 | 0.020 |
Why?
|
Nuclear Family | 1 | 2013 | 311 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2005 | 2965 | 0.020 |
Why?
|
Animals | 7 | 2024 | 169408 | 0.020 |
Why?
|
Coloring Agents | 1 | 2014 | 564 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2014 | 993 | 0.020 |
Why?
|
Mammary Tumor Virus, Mouse | 1 | 2011 | 41 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2004 | 3269 | 0.020 |
Why?
|
California | 1 | 2015 | 1443 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1794 | 0.020 |
Why?
|
Contraception | 1 | 2014 | 362 | 0.020 |
Why?
|
Lysine | 1 | 2015 | 1000 | 0.020 |
Why?
|
Fertility | 1 | 2015 | 770 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2010 | 3811 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2015 | 1524 | 0.020 |
Why?
|
Contrast Media | 1 | 2024 | 5334 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2011 | 2848 | 0.020 |
Why?
|
Exons | 1 | 2016 | 2395 | 0.020 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2010 | 127 | 0.020 |
Why?
|
Mediastinal Neoplasms | 1 | 1993 | 403 | 0.020 |
Why?
|
Pancreas | 1 | 2017 | 1700 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3621 | 0.020 |
Why?
|
Myosins | 1 | 1991 | 408 | 0.020 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.020 |
Why?
|
Fallopian Tubes | 1 | 2010 | 179 | 0.020 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2009 | 67 | 0.020 |
Why?
|
Granulocytes | 1 | 1991 | 551 | 0.020 |
Why?
|
Oxidants | 1 | 2010 | 168 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 1369 | 0.020 |
Why?
|
Internet | 1 | 2021 | 3112 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1516 | 0.020 |
Why?
|
Mammary Glands, Animal | 1 | 2011 | 273 | 0.020 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 213 | 0.020 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2009 | 98 | 0.020 |
Why?
|
Leukemia, Myeloid | 1 | 1992 | 693 | 0.020 |
Why?
|
Registries | 3 | 2014 | 8384 | 0.020 |
Why?
|
Menotropins | 1 | 2008 | 41 | 0.020 |
Why?
|
Rad51 Recombinase | 1 | 2009 | 191 | 0.020 |
Why?
|
RNA Helicases | 1 | 2009 | 144 | 0.020 |
Why?
|
DNA-Binding Proteins | 3 | 2010 | 9618 | 0.020 |
Why?
|
Bromocriptine | 1 | 2008 | 93 | 0.020 |
Why?
|
Clomiphene | 1 | 2008 | 72 | 0.020 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2009 | 146 | 0.020 |
Why?
|
Estrogen Receptor Modulators | 1 | 2008 | 58 | 0.020 |
Why?
|
Endodeoxyribonucleases | 1 | 2009 | 166 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 2011 | 697 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2019 | 3473 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 8055 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2009 | 346 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3951 | 0.020 |
Why?
|
Phylogeny | 1 | 2015 | 2843 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12469 | 0.020 |
Why?
|
Gestational Age | 1 | 2016 | 3610 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2021 | 3925 | 0.020 |
Why?
|
Anthropometry | 1 | 2012 | 1343 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4651 | 0.020 |
Why?
|
Exercise | 1 | 2023 | 5953 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2011 | 1498 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 742 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2931 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2009 | 751 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5800 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6805 | 0.020 |
Why?
|
Mice, SCID | 1 | 2011 | 2631 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2022 | 26394 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2012 | 1780 | 0.020 |
Why?
|
Stomach Neoplasms | 2 | 2007 | 1483 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2784 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 2009 | 6131 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10397 | 0.010 |
Why?
|
Disease Progression | 2 | 2014 | 13677 | 0.010 |
Why?
|
Computational Biology | 1 | 2016 | 3562 | 0.010 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 1560 | 0.010 |
Why?
|
Genetic Heterogeneity | 1 | 2007 | 737 | 0.010 |
Why?
|
Vietnam | 1 | 2004 | 415 | 0.010 |
Why?
|
Menstruation | 1 | 2005 | 310 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4593 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9344 | 0.010 |
Why?
|
Leukocytes | 1 | 1991 | 2034 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1993 | 1437 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3836 | 0.010 |
Why?
|
Down-Regulation | 1 | 2010 | 2941 | 0.010 |
Why?
|
Mice | 3 | 2018 | 82074 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8888 | 0.010 |
Why?
|
RNA Interference | 1 | 2011 | 2835 | 0.010 |
Why?
|
Premenopause | 1 | 2006 | 1039 | 0.010 |
Why?
|
Reference Values | 1 | 2009 | 4941 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2011 | 17629 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2010 | 2885 | 0.010 |
Why?
|
Body Weight | 1 | 2012 | 4628 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8745 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2011 | 5905 | 0.010 |
Why?
|
Antigens, CD | 1 | 2010 | 4032 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3721 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2004 | 1328 | 0.010 |
Why?
|
Functional Laterality | 1 | 2006 | 2269 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6879 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2010 | 3138 | 0.010 |
Why?
|
Antimalarials | 1 | 2004 | 908 | 0.010 |
Why?
|
Israel | 1 | 2000 | 726 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6289 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2012 | 5342 | 0.010 |
Why?
|
Regression Analysis | 1 | 2006 | 6346 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9499 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14485 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2011 | 19023 | 0.010 |
Why?
|
Algorithms | 1 | 2015 | 14199 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2011 | 5707 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1991 | 11934 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9264 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1993 | 372 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 22381 | 0.010 |
Why?
|
Brain | 1 | 2019 | 27476 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2004 | 2543 | 0.010 |
Why?
|
Chromosome Inversion | 1 | 1992 | 119 | 0.010 |
Why?
|
Peptide Mapping | 1 | 1991 | 260 | 0.010 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 1991 | 348 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2004 | 3233 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1991 | 1057 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 1991 | 1305 | 0.010 |
Why?
|
Chickens | 1 | 1991 | 845 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 1992 | 2126 | 0.000 |
Why?
|
Signal Transduction | 1 | 2010 | 23652 | 0.000 |
Why?
|
Child | 2 | 2005 | 80969 | 0.000 |
Why?
|
Radiotherapy Dosage | 1 | 1993 | 2920 | 0.000 |
Why?
|
Translocation, Genetic | 1 | 1992 | 1395 | 0.000 |
Why?
|
Remission Induction | 1 | 1992 | 2411 | 0.000 |
Why?
|
Bone Marrow Transplantation | 1 | 1992 | 2709 | 0.000 |
Why?
|
Transplantation, Homologous | 1 | 1992 | 4835 | 0.000 |
Why?
|
Immunologic Factors | 1 | 1992 | 1597 | 0.000 |
Why?
|
Infant | 1 | 2004 | 36541 | 0.000 |
Why?
|
Child, Preschool | 1 | 2004 | 42684 | 0.000 |
Why?
|
Acute Disease | 1 | 1992 | 7245 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1991 | 13427 | 0.000 |
Why?
|